Tema Oncology ETF Rating $41.48 -1.33 (-3.11%) Closing price 03:59 PM EasternExtended Trading$41.46 -0.01 (-0.04%) As of 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsNews and TrendsOwnershipRatingsShort Interest Tema Oncology ETF Aggregate Rating and Price Target (2026)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.CANC Aggregate RatingModerate Buy 2.75Holdings in CANC have an aggregate rating of Moderate Buy based on 379 analyst ratings issued in the past year covering 23 companies (69.7% of the portfolio).CANC Aggregate Price Target$41.48High Prediction$41.48Average Prediction$41.48Low Prediction$41.48Holdings in CANC have an aggregate price target of $41.48 and a range of $41.48 to $41.48 covering 23 companies (69.7% of the portfolio).CANC Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy1 Buy rating(s)Moderate Buy19 Moderate Buy rating(s)Hold3 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Tema Oncology ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 23 CANC Holdings ExportWeight In ETFCompanyShare PriceConsensus RatingConsensus Price TargetPossible UpsideNumber of RatingsMarketRank™Indicator(s)ViewRatings5.51%RVMDRevolution Medicines$190.74-1.1%Moderate Buy$228.21 19.6%223.3333 of 5 starsAnalyst Forecast4.87%COGTCogent Biosciences$31.41-3.7%Moderate Buy$51.56 64.1%122.0259 of 5 stars4.62%MRKMerck & Co., Inc.$148.07-1.9%Moderate Buy$154.24 4.2%244.2903 of 5 starsTrending NewsAnalyst Upgrade4.51%LLYEli Lilly and Company$1,153.69-1.4%Moderate Buy$1,305.25 13.1%304.8223 of 5 starsTrending NewsAnalyst ForecastAnalyst Revision3.55%ABBVAbbVie$265.43+0.1%Moderate Buy$276.64 4.2%253.8618 of 5 starsTrending News3.55%BMYBristol Myers Squibb$61.14-1.8%Moderate Buy$67.06 9.7%254.7381 of 5 starsAnalyst Forecast3.24%JNJJohnson & Johnson$269.01-0.1%Moderate Buy$274.13 1.9%254.4283 of 5 starsTrending NewsAnalyst ForecastAnalyst Revision3.19%ONCBeOne Medicines$365.00-0.8%Buy$402.71 10.3%172.7551 of 5 starsAnalyst UpgradeHigh Trading Volume3.17%RHHBYRoche$55.06-1.1%Moderate Buy$60.00 9.0%123.5034 of 5 starsTrending News3.09%GMABGenmab A/S$34.75-1.3%Moderate Buy$39.50 13.7%134.2685 of 5 stars3.00%HALOHalozyme Therapeutics$112.44-2.3%Moderate Buy$91.20 -18.9%133.0773 of 5 stars2.85%EXELExelixis$56.73-2.4%Hold$50.29 -11.4%202.3428 of 5 stars2.78%CGONCG Oncology$73.36-5.6%Moderate Buy$87.78 19.7%113.0062 of 5 stars2.73%IMNMImmunome$24.24-5.9%Moderate Buy$35.18 45.1%132.7108 of 5 starsAnalyst Forecast2.64%IDYAIDEAYA Biosciences$37.46-5.7%Moderate Buy$52.69 40.7%153.0356 of 5 starsAnalyst ForecastHigh Trading Volume2.54%ELVNEnliven Therapeutics$46.09-4.4%Moderate Buy$75.00 62.7%92.2671 of 5 starsInsider Trade2.44%BBIOBridgeBio Pharma$65.71-5.1%Moderate Buy$102.61 56.2%233.3701 of 5 starsInsider Trade2.12%ERASErasca$13.94-10.4%Moderate Buy$22.09 58.5%112.1855 of 5 stars2.06%RLAYRelay Therapeutics$18.03-6.8%Moderate Buy$25.92 43.7%142.3775 of 5 stars1.97%ZLABZai Lab$26.44+0.1%Moderate Buy$37.25 40.9%71.8762 of 5 starsNews Coverage1.75%IOVAIovance Biotherapeutics$10.19-4.2%Hold$9.11 -10.6%111.5565 of 5 stars1.75%CELCCelcuity$79.99-4.9%Moderate Buy$154.75 93.5%122.7278 of 5 stars1.73%LEGNLegend Biotech$18.45-1.0%Hold$53.14 188.0%153.3345 of 5 stars This page (NASDAQ:CANC) was last updated on 9/23/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tema Oncology ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Tema Oncology ETF With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
